Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Andrea Koch,1 Emilio Pizzichini,2 Alan Hamilton,3 Lorna Hart,3 Lawrence Korducki,4 Maria Cristina De Salvo,5 Pierluigi Paggiaro6 1Medical Clinic III for Pneumology, Allergology, Sleep and Respiratory Medicine, University Hospital Bochum-Bergmannsheil, Bochum, Germany; 2NUPAIVA (Asthma Research Cent...

Full description

Bibliographic Details
Main Authors: Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P
Format: Article
Language:English
Published: Dove Medical Press 2014-07-01
Series:International Journal of COPD
Online Access:http://www.dovepress.com/lung-function-efficacy-and-symptomatic-benefit-of-olodaterol-once-dail-a17481

Internet

http://www.dovepress.com/lung-function-efficacy-and-symptomatic-benefit-of-olodaterol-once-dail-a17481

Similar Items